 Elaine Martis will now present the closing perspective and it's an honor and a pleasure to have you here to give us your perspective. Thanks David, really appreciate that and this is the fun part of being a meeting organizer I guess is that I get to sum up. I just have a few quick slides that I wanted to use to sort of portray the momentum of the project but also give you a flavor of what's underway as I see TCGA is something that's sort of growing and morphing and changing as we learn more and are able to do more within the network that we've generated and it certainly has been as a person who's been involved in this network for some time now I'm very exciting and gratifying to see not only the number of people attending the meeting from outside the TCGA network but to also see the exciting applications of the data including especially the last two talks really beginning to reach out to the clinical aspects of the disease and begin to impact all of that. So I just put together a few slides which I'm not any better at advancing than anyone else was apparently. There we go. So as many of you know from Eric's opening comments the original notion of TCGA came from a 2005 white paper and you can see here that the short term goals were milestones such as samples collected and analyzed and data made accessible but we're already seeing at this meeting a longer term beginning to move towards impacting the lives of patients and I think that's only going to be more evident as we go forward in time. One of the great aspects of this project that's really been driven forward over just the last year as you can see is the difference in the number of tumor types and the multitude of different types of data that are going through our pipelines now across many, many tumor types and you've heard examples of that throughout the meeting this week but the bottom graph really represents where we're at and I'll tell you a little bit more about where the future is going to take us. Part of all of this is the aspect of big science so we're seeing the benefits of this and this is really following on the heels of other large science projects such as the Human Genome Project as well as the HapMap and 1000 Genomes projects that have been mentioned here as well as others and you know it's true that and really we've seen great evidence that these big science projects have multitudes of spin-offs for other people in terms of the different kinds of analyses that can be done and the ultimate downstream benefits to biomedical knowledge that are created and I think this is one of the values of having big science projects as Eric articulated as well earlier. So right now there's a status report for your consideration in terms of data available from all of the tumor projects. You can see multiple thousands of tumor normal pairs in terms of in the pipeline at various stages and data becoming available and this will continue as we move forward on these multiple tumor types that I just showed. This really just exemplifies the notion behind TCGA which is not to take DNA data or RNA data or what have you in a vacuum but rather to try and integrate it across the data types as shown and I think these are some of the most exciting challenges that we have ahead of us is really coming up with intelligent and informative data integration approaches. You've seen a few examples at this meeting. I think there are others that are underway and the multitude of data types I think will really drive this because there are of course many, many ways in which a gene can be altered in the context of oncogenesis. So this is my bold prediction, mine and mine alone I should point out. I think 2012 is going to be the year of TCGA post pilot publications and I've just listed some of the projects here that are really well along, several of which I'm happy to be a part of including AML, breast and endometrial cancer but there are going to be I think some very exciting primary publications as well as supporting ancillary data analyses coming out of these projects just in this next calendar year and this is probably an underestimate at this point in time but these are the ones that I know the most about. In addition to the exome capture and I think again this was alluded to in several talks there are whole genome sequencing approaches going on in multiple tumor types and this will end up being important moving forward because this gives you more a sense of the multitude of genomic alterations that aren't always captured by exome data and will better understand how structural variants for example are going to impact tumor genomics. So expanding the enterprise so just a couple of last slides on where this is all going I've listed some examples here some pilot projects that were announced this week at the steering committee meeting including looks into formal and fixed paraffin embedded preserved tissues of course as many of you know who do biobanking or tissue banking there is a wealth of data just waiting for us to mine out of formal and fixed paraffin embedded tissues but of course these present significant challenges to the quality and quantities of DNA and RNA that are available nonetheless I think they deserve some careful attention and we have some pilot projects that are approved now for this tissue type of preservation. I'll show some data next on mouse models of human cancers but these provide us some of the most important experimental models especially as we move into targeted therapies, vaccines and other aspects of human cancer care and so I think it's important to begin characterizing these within the TCGA landscape as well for that further downstream use. We also have initially agreed to go forward on projects to study rare tumor types and there will be more data or choices coming out of those soon but the notion here is that while you have smaller numbers of tissues available for study we will still continue to apply this comprehensive focus of assays and analysis that you've heard about in the last day and a half. As far as integration efforts for TCGA data with other projects that are ongoing there are two to mention and one is sort of an obvious mention which is integrating with the International Cancer Genomics Consortium so that we have a more global view of cancer if you will and I think there are well recognized population specific differences etc. across cancer types and I think this will be incredibly informative for everyone and expands the reach of TCGA data beyond the United States and Canada. And then lastly integration efforts which we heard about there was a coincident meeting going on here for CPTAC which is an NCI funded project to look at proteomics of cancer and what the proteomics folks are finding out is that if we know about the genomics of cancer that can be tremendously informative in proteomic investigations and of course this provides a very rich data set for these downstream proteomics efforts so there will be integration and interface between TCGA across several selected tumor types breast ovarian and colorectal moving into these funded CPTAC groups in proteomic investigation so I think that will be sort of like the gravy on the potatoes if you will. And so then I just wanted to say a couple of words about these specific areas so I was very honored to be named the chair of this mouse TCGA committee member by Dr. Varmas and this included several luminaries in the mouse models of human cancer listed here under me I'm not such a luminary but then Kenna was also the guiding force in keeping us all on track. And basically what we did was solicit information from the mouse models community on different models that were available for human cancer the results were overwhelming almost a hundred different types of cancer models were referred into us with information about them and I'm just listing the four here that we selected as a group for the initial look in this pilot project so they include a prostate cancer model that is a gem a genetically engineered model a melanoma model that is driven by a known carcinogen and then a non small cell lung cancer model another carcinogen driven model from urethane injection and then noting the incredible amount of samples and data that are coming out of human breast cancer studies in TCGA we selected several breast cancer models for mouse so we're underway with some of the nuts and bolts paperwork of getting these samples into the BCR identifying pathologists who understand what mouse tumors look like as opposed to human tumors the gratifying thing there is that there are a lot of veterinary pathologists out there who are keen to help out and so you'll see most of these hopefully moving into the new year as identified pilot projects for which data will be available and then I already mentioned sort of the nuts and bolts aspects of the CPT CPTAC interaction here and we sorted out some of the early details of that yesterday during a lunchtime meeting so I think that'll be an exciting new enterprise for TCGA data to play in so what are the next steps well first of all as an organizer I want to thank everybody for attending and for those last few of you here that are stayed on to the better end especially thank you for staying I think it's been a great interaction this week and we're looking forward to more certainly as a meeting organizer I would be low to suggest that that we can't make this meeting better so if you have ideas please provide those to myself Linda or to Kenna and her staff and just before the the last bullet point I also wanted to mention that putting conferences like this together as many of you know who have ever organized things are not straightforward enterprises there are lots of what ifs and last minute things that need to be paid attention to so in that regard could we please give a warm round of applause for not only the NCI and NHGRI staffs that were involved in the planning of this but also to capital consulting for excellent organization and while I'm at it to the outstanding audio visual staff at the back who advanced our slides for us OK and then lastly the big looming question is will we do this again absolutely I think that the response this time has been more than we anticipated and we'll look forward to seeing you again please look for timing and announcements for the second symposium and with that I will thank you and invite you to partake in lunch which is waiting outside thanks very much really really a successful meeting